ResearcherNanjing University of Chinese MedicineNo recent work listed

Wenjing Ji

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. Co-author DOI 10.1016/j.ejphar.2023.175703 ↗
Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells. Co-author DOI 10.3390/molecules27092747 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Peng Cao · 2 shared papers, 2022–2023 · strength 0.33
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703 ↗
- Paper Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cel… DOI 10.3390/molecules27092747 ↗
Xueting Cai · 1 shared paper, 2023 · strength 0.17
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703 ↗
Weikang Kong · 1 shared paper, 2023 · strength 0.17
- Paper Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer. DOI 10.1016/j.ejphar.2023.175703 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.